JP2012524092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524092A5 JP2012524092A5 JP2012506123A JP2012506123A JP2012524092A5 JP 2012524092 A5 JP2012524092 A5 JP 2012524092A5 JP 2012506123 A JP2012506123 A JP 2012506123A JP 2012506123 A JP2012506123 A JP 2012506123A JP 2012524092 A5 JP2012524092 A5 JP 2012524092A5
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- pharmaceutical composition
- peg
- crystallization inhibitor
- inhibitor component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 21
- 239000002775 capsule Substances 0.000 claims 20
- 239000002202 Polyethylene glycol Substances 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 229920001223 polyethylene glycol Polymers 0.000 claims 18
- 238000002425 crystallisation Methods 0.000 claims 15
- 230000008025 crystallization Effects 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 15
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 14
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 8
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 claims 7
- 229920001531 copovidone Polymers 0.000 claims 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 108010010803 Gelatin Proteins 0.000 claims 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 239000007903 gelatin capsule Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims 2
- 239000011118 polyvinyl acetate Substances 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- FYLZPFSWVMMCQC-UHFFFAOYSA-N 5,5,5-trifluoropentanamide Chemical compound NC(=O)CCCC(F)(F)F FYLZPFSWVMMCQC-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16906109P | 2009-04-14 | 2009-04-14 | |
| US61/169,061 | 2009-04-14 | ||
| PCT/US2010/030862 WO2010120755A1 (en) | 2009-04-14 | 2010-04-13 | Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012524092A JP2012524092A (ja) | 2012-10-11 |
| JP2012524092A5 true JP2012524092A5 (https=) | 2013-03-28 |
Family
ID=42235859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506123A Pending JP2012524092A (ja) | 2009-04-14 | 2010-04-13 | アモルファスアルファ−（ｎ−スルホンアミド）アセトアミド化合物の生物学的に利用可能なカプセル組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8252821B2 (https=) |
| EP (1) | EP2419090B1 (https=) |
| JP (1) | JP2012524092A (https=) |
| KR (1) | KR20120022766A (https=) |
| CN (1) | CN102395361A (https=) |
| AR (1) | AR076305A1 (https=) |
| AU (1) | AU2010236602A1 (https=) |
| BR (1) | BRPI1015483A2 (https=) |
| CA (1) | CA2758847A1 (https=) |
| EA (1) | EA201101286A1 (https=) |
| MX (1) | MX2011010514A (https=) |
| NZ (1) | NZ595335A (https=) |
| TW (1) | TW201041609A (https=) |
| WO (1) | WO2010120755A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2471099C (en) | 2001-12-20 | 2011-04-12 | Bristol-Myers Squibb Company | .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| WO2011040797A2 (ko) | 2009-10-02 | 2011-04-07 | 엘지전자 주식회사 | 하향링크 참조신호의 전송방법 및 장치 |
| ES2565353T3 (es) | 2010-12-16 | 2016-04-04 | Borje S. Andersson | Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol |
| DK2701684T3 (en) | 2011-04-28 | 2017-09-18 | Platform Brightworks Two Ltd | Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use |
| US20130302414A1 (en) * | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US20220175760A1 (en) * | 2019-02-22 | 2022-06-09 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
| EP3953345B1 (en) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Pyridine rings containing derivatives as malt1 inhibitors |
| JP2023538099A (ja) * | 2020-08-21 | 2023-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5274094A (en) | 1990-08-15 | 1993-12-28 | British Bio-Technology Limited | Production of heterobicyclic containing benzene sulfonamides |
| GB9202791D0 (en) | 1992-02-11 | 1992-03-25 | British Bio Technology | Compounds |
| SK282833B6 (sk) | 1995-11-17 | 2002-12-03 | Warner-Lambert Company | Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory |
| JP2000515153A (ja) | 1996-07-22 | 2000-11-14 | モンサント カンパニー | チオールスルホンアミド メタロプロテアーゼインヒビター |
| JP2001523221A (ja) * | 1996-09-01 | 2001-11-20 | ファーモス コーポレイション | 親油性物質の促進された生物学的利用能のための固形共沈物 |
| JPH11343279A (ja) | 1998-03-16 | 1999-12-14 | Shionogi & Co Ltd | スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤 |
| AU766192B2 (en) | 1999-01-27 | 2003-10-09 | Wyeth Holdings Corporation | Acetylenic sulfonamide thiol tace inhibitors |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| NZ514453A (en) | 1999-02-26 | 2003-04-29 | Merck & Co Inc | Novel sulfonamide compounds and uses thereof |
| IL160761A0 (en) * | 2001-10-19 | 2004-08-31 | Isotechnika Inc | Novel cyclosporin analog microemulsion preconcentrates |
| CA2471099C (en) | 2001-12-20 | 2011-04-12 | Bristol-Myers Squibb Company | .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors |
| KR20060002908A (ko) | 2003-03-31 | 2006-01-09 | 와이어쓰 | 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체 |
| CA2544350A1 (en) | 2003-10-29 | 2005-05-12 | Elan Pharmaceuticals, Inc. | N-substituted benzene sulfonamides |
| US7163942B2 (en) | 2004-04-01 | 2007-01-16 | Pfizer Inc. | Sulfonamide compounds for the treatment of neurodegenerative disorders |
| CA2595116A1 (en) * | 2004-04-28 | 2005-11-10 | Procarrier, Inc. | Oral formulation for delivery of poorly absorbed drugs |
| EP1768960A1 (en) | 2004-07-13 | 2007-04-04 | F.Hoffmann-La Roche Ag | Sulfonamide derivatives |
| US7144894B2 (en) | 2004-09-23 | 2006-12-05 | Bristol-Myers Squibb Company | Sulfonamide bicyclic compounds |
| WO2006065710A1 (en) * | 2004-12-14 | 2006-06-22 | Wyeth | Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders |
| AR059517A1 (es) | 2006-02-17 | 2008-04-09 | Wyeth Corp | N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo |
| EP1984321A1 (en) | 2006-02-17 | 2008-10-29 | Wyeth | Methods for preparing sulfonamide substituted alcohols and intermediates thereof |
| WO2007103683A2 (en) * | 2006-03-01 | 2007-09-13 | Roskamp Research Llc | Compounds for inhibiting beta-amyloid production |
| WO2008112249A1 (en) | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| WO2009005688A2 (en) | 2007-06-29 | 2009-01-08 | Trustees Of Columbia University In The City Of New York | Activating mutations in notch-1 |
| US8084477B2 (en) * | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| WO2009137657A1 (en) | 2008-05-08 | 2009-11-12 | Bristol-Myers Squibb Company | 2-aryl glycinamide derivatives |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| CN102438622A (zh) | 2009-03-19 | 2012-05-02 | 百时美施贵宝公司 | 作为β淀粉样肽产生抑制剂的新颖α-(N-磺酰氨基)乙酰胺化合物 |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US20110071199A1 (en) | 2009-03-20 | 2011-03-24 | Bristol-Myers Squibb Company | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease |
| TW201043269A (en) | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
-
2010
- 2010-04-12 US US12/758,385 patent/US8252821B2/en not_active Expired - Fee Related
- 2010-04-13 CN CN2010800164919A patent/CN102395361A/zh active Pending
- 2010-04-13 CA CA2758847A patent/CA2758847A1/en not_active Abandoned
- 2010-04-13 EP EP10714418A patent/EP2419090B1/en not_active Not-in-force
- 2010-04-13 BR BRPI1015483A patent/BRPI1015483A2/pt not_active IP Right Cessation
- 2010-04-13 JP JP2012506123A patent/JP2012524092A/ja active Pending
- 2010-04-13 MX MX2011010514A patent/MX2011010514A/es active IP Right Grant
- 2010-04-13 EA EA201101286A patent/EA201101286A1/ru unknown
- 2010-04-13 AU AU2010236602A patent/AU2010236602A1/en not_active Abandoned
- 2010-04-13 KR KR1020117024036A patent/KR20120022766A/ko not_active Withdrawn
- 2010-04-13 NZ NZ595335A patent/NZ595335A/xx not_active IP Right Cessation
- 2010-04-13 WO PCT/US2010/030862 patent/WO2010120755A1/en not_active Ceased
- 2010-04-14 TW TW099111671A patent/TW201041609A/zh unknown
- 2010-04-14 AR ARP100101257A patent/AR076305A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524092A5 (https=) | ||
| JP6043785B2 (ja) | 注意欠陥障害の処置のための方法および組成物 | |
| NZ595335A (en) | Pharmaceutical comprising (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide with enhanced bioavailability and solubility | |
| JP2015512406A5 (https=) | ||
| JP2010270124A5 (https=) | ||
| TWI638654B (zh) | 用以治療中樞神經系統疾病之包含苯甲酸鹽化合物及鞣酸的組合物 | |
| ES2868231T3 (es) | Métodos de tratamiento de enfermedades usando compuestos de isoindolina | |
| TW200916103A (en) | Therapeutic compositions and methods | |
| JP2016535777A5 (https=) | ||
| JP2015524444A5 (https=) | ||
| RU2016141569A (ru) | Комбинации | |
| IL298998B1 (en) | Pharmaceutical formulations of a hif hydroxylase inhibitor | |
| RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
| JP2006508953A5 (https=) | ||
| JP2018168191A5 (https=) | ||
| JP2017522300A5 (https=) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2018521007A5 (https=) | ||
| JP2009517411A5 (https=) | ||
| JP2014507475A5 (https=) | ||
| JP2018039810A5 (https=) | ||
| JP2012520896A5 (https=) | ||
| JP2023531930A5 (https=) | ||
| KR20180074707A (ko) | 저 용량 경구 디피리다몰 조성물 및 이의 용도 | |
| CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 |